Revisiting Post-ICU Admission Fluid Balance Across Pediatric Sepsis Mortality Risk Strata: A Secondary Analysis of a Prospective Observational Cohort Study.

Post-ICU admission cumulative positive fluid balance (PFB) is associated with increased mortality among critically ill patients. We sought to test whether this risk varied across biomarker-based risk strata upon adjusting for illness severity, presence of severe acute kidney injury (acute kidney injury), and use of continuous renal replacement therapy (CRRT) in pediatric septic shock. Ongoing multicenter prospective observational cohort. Thirteen PICUs in the United States (2003-2023). Six hundred and eighty-one children with septic shock. None. Cumulative percent PFB between days 1 and 7 (days 1-7 %PFB) was determined. Primary outcome of interest was complicated course defined as death or persistence of greater than or equal to two organ dysfunctions by day 7. Pediatric Sepsis Biomarker Risk Model (PERSEVERE)-II biomarkers were used to assign mortality probability and categorize patients into high mortality ( Our data demonstrate the influence of cumulative %PFB on the risk of complicated course in pediatric septic shock. Contrary to our previous report, this risk was largely driven by patients categorized as having a high mortality risk based on PERSEVERE-II biomarkers. Incorporation of such prognostic enrichment tools in randomized trials of restrictive fluid management or early initiation of de-escalation strategies may inform targeted application of such interventions among at-risk patients.

Informations de copyright

Copyright © 2024 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of the Society of Critical Care Medicine.

Déclaration de conflit d'intérêts

Dr. Atreya and Cincinnati Children’s Hospital (CCHMC) hold a provisional patent for a unified biomarker model—PERSEVERENCE that incorporates Pediatric Sepsis Biomarker Risk Model (PERSEVERE) and endothelial dysfunction markers to predict the risk of multiple organ dysfunctions in sepsis. Dr. Atreya received funding through the Cincinnati Children’s Research Foundation (CCRF) Procter-Scholar Award. Dr. Stanski and CCHMC hold a provisional patent for the use of PERSEVERE biomarkers in sepsis-associated acute kidney injury. Dr. Stanski is supported by the National Center for Advancing Translational Sciences of the National Institutes of Health (NIH) (KL2TR001426). Dr. Atreya, Dr. Stanski, and CCHMC hold a provisional patent for PERSEVERENCE sepsis-associated acute kidney injury model to identify high-risk patients for microvascular modulating therapies. Dr. Fitzgerald, Dr. Weiss, Dr. Haileselassie, Dr. Quasney, and Dr. Alder received funding from the NIH.